Researchers have discovered that psilocybin, the active compound in magic mushrooms, may help prevent a painful side effect that affects about 60% of chemotherapy patients. A study published in Science on September 3 by researchers at the University of Texas MD Anderson Cancer Center showed that psilocybin protected mice from chemotherapy-induced peripheral neuropathy, a nerve condition that causes numbness, burning, and pain in the hands and feet. The findings open a new avenue for treating one of cancer care's most stubborn problems: there is currently no effective treatment for this type of nerve damage, and some patients stop chemotherapy entirely because the pain becomes unbearable.

How Does Psilocybin Protect Against Chemo Nerve Damage?

In the study, mice that received two doses of psilocybin before chemotherapy treatment showed protection from nerve damage across up to six cycles of cisplatin, a platinum-based chemotherapy drug. The researchers chose psilocybin because it has a favorable safety profile and because earlier studies suggested it could stimulate new nerve branches that might shield against damage. Importantly, the protection wasn't unique to psilocybin. When researchers tested tabernanthalog, a non-hallucinogenic compound that also binds to the same brain receptor as psilocybin, it provided similar nerve protection. This suggests the therapeutic benefit comes from how these compounds interact with the brain's serotonin system, not from the psychedelic experience itself.

The research team is now preparing to move into human testing. A clinical trial is expected to begin by November, comparing psilocybin to standard supportive care and placebo in patients with colorectal, breast, and head and neck cancers undergoing chemotherapy. While the mouse studies are promising, researchers emphasize that results in animals don't automatically translate to humans, making the upcoming trial crucial for understanding whether this approach could become a real treatment option.

What Other Psychedelic Treatments Are Moving Forward?

Beyond psilocybin, the psychedelic medicine landscape is expanding rapidly. Definium Therapeutics announced on September 10 that the FDA granted Breakthrough Therapy designation for DT120, an oral formulation of LSD engineered for faster absorption and fewer gastrointestinal side effects. This is Definium's second Breakthrough Therapy designation; the company previously received one for the same compound in treating generalized anxiety disorder. In clinical trials, patients with major depressive disorder who received DT120 showed significant improvement at six weeks after dosing, scoring 13 points lower on a standard depression assessment scale, where a six-point decrease is considered meaningful.

The FDA awards Breakthrough Therapy designation to drugs that show potential to be a significant improvement over current treatments for serious conditions. This status helps expedite development and review. Several psychedelic drugs have now received this designation, including MDMA for post-traumatic stress disorder (PTSD), psilocybin for treatment-resistant depression and major depressive disorder, and newer compounds like 5-MeO-DMT and luvesilocin for depression and postpartum depression.

Steps to Understanding Psychedelic Medicine Development

• Breakthrough Therapy Designation: The FDA grants this status to drugs showing significant promise over existing treatments for serious conditions, which speeds up the development and review process and signals regulatory confidence in the approach.
• Clinical Trial Phases: Psychedelic medicines move through Phase 2 trials (testing in larger groups for efficacy and safety) and Phase 3 trials (large, multi-site studies comparing to placebo) before potential FDA approval, with a new Phase 2 psilocybin trial for major depression set to launch in 2027.
• Mechanism of Action: Most psychedelics work by binding to serotonin receptors in the brain, which alters neural connectivity and may facilitate psychological insight when combined with therapy, distinguishing them from traditional antidepressants.
• Regulatory Scrutiny: The FDA is holding a public hearing on September 14 to discuss provider training, patient safety, access considerations, and data standardization for psychedelic treatments.

What Does the Evidence Show for MDMA and PTSD?

A meta-analysis published in September 2026 synthesized data from seven randomized controlled trials and found that MDMA-assisted psychotherapy leads to significant improvements in PTSD symptoms, depression, and functional disability compared to placebo or low-dose MDMA controls. The analysis included both published and unpublished studies completed by June 2025, which helps reduce bias from selective reporting. MDMA is believed to work by modulating fear responses, enhancing emotional openness, and supporting the therapeutic relationship during supervised sessions, typically involving two to three MDMA-assisted therapy sessions integrated within a broader psychotherapy protocol.

Despite the promising findings, the meta-analysis highlighted several limitations. Most trials enrolled fewer than 100 participants, and all included studies were sponsored by a single organization, raising concerns about generalizability and potential sponsor bias. The field also faces challenges with maintaining effective blinding in psychedelic trials, since the noticeable psychoactive effects can make it difficult to keep participants unaware of whether they received the active drug or placebo. Additionally, the review found that MDMA-assisted therapy did not significantly improve sleep quality, a common problem in PTSD, suggesting that additional treatments may be needed for comprehensive symptom management.

"Getting this approval and getting started with these treatments is what I hope will move us towards more public support and more general access," said Dr. Gary Wynn, one of two New Zealand psychiatrists authorized to administer MDMA for PTSD.

Dr. Gary Wynn, Psychiatrist, New Zealand

New Zealand recently joined Australia in permitting authorized psychiatrists to administer MDMA for PTSD. On September 4, New Zealand's Medsafe regulatory body approved two psychiatrists to provide MDMA treatment to adults with PTSD. However, access remains limited. Each round of treatment costs approximately $9,000 USD, and a standard course includes three rounds of MDMA along with 54 hours of therapy. With no public health funding allocated for these treatments in New Zealand, questions remain about whether patients can realistically access them.

What Challenges Remain for Psychedelic Medicine?

As psychedelic treatments advance toward potential FDA approval, several unresolved questions persist. The durability of antidepressant effects beyond several months remains uncertain, and the risk profile in larger, more diverse populations is not fully understood. Adverse events such as anxiety, transient psychosis, or cardiovascular effects have been reported in trials, and long-term safety data, particularly regarding repeated dosing in people with complex medical histories, remain limited.

The integration of psychotherapy and training of facilitators also varies across research sites, raising questions about standardization and scalability if these therapies eventually gain FDA approval. The FDA's upcoming public hearing on September 14 will address these implementation challenges, including provider credentialing, patient safety protocols, and best practices for data collection. As the field moves forward, careful attention to trial design, transparent reporting, and real-world implementation will determine whether psychedelic-assisted therapies can fulfill their potential as transformative treatments for conditions like depression, PTSD, and chemotherapy-related pain.

" }